Mr. Lucas Zimmerman reports

OPTIMI HEALTH ANNOUNCES CLOSING OF OVERSUBSCRIBED US$15 MILLION PUBLIC OFFERING

Optimi Health Corp. today closed its previously announced underwritten public offering in connection with the uplisting of its common shares to the Nasdaq Capital Market. The company issued 2.4 million common shares at a price of $6.25 (U.S.) per share. The aggregate gross proceeds to the company from the offering were $15-million (U.S.), before deducting underwriting discounts and offering expenses.

"This marks a significant milestone for Optimi," said Dane Stevens, chief executive officer of Optimi. "This financing provides significant strength to our balance sheet and represents the necessary working capital for the growth of our business, with ample runway to scale over the next few years. We are thrilled to welcome a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of psychedelic medicine."

The common shares began trading on the Nasdaq Capital Market on May 20, 2026, under the symbol OPTH. The company's common shares will continue to trade on the Canadian Securities Exchange under the symbol OPTI. All securities issued under the offering were issued free from any resale restrictions under applicable Canadian and United States securities laws.

Pursuant to an underwriting agreement dated May 19, 2026, between Joseph Gunnar & Co. LLC and the company, the underwriter acted as sole book-running manager for the offering. The company granted 96,000 non-transferable common share purchase warrants entitling the underwriter to purchase up to an aggregate of 96,000 common shares of the company at a price of $7.50 (U.S.) per share until May 21, 2031, and paid certain offering expenses of the underwriter.

A registration statement on Form F-1 (file No. 333-290086) related to the offering of the shares described above was filed with the United States Securities and Exchange Commission (SEC) and was declared effective on May 19, 2026. A copy of the registration statement can be accessed by visiting the SEC website. The common shares were offered and sold in the United States only by means of a prospectus forming part of the registration statement. A final prospectus relating to this offering has been filed with the SEC and may be obtained from Joseph Gunnar, prospectus department, 40 Wall St. (30th floor), New York, N.Y., 10005, telephone: 212-440-9600, e-mail: prospectus@jgunnar.com. Investors may also obtain these documents at no cost by visiting the SEC's website.

In Canada, the offering was completed in reliance on the listed issuer financing exemption from the prospectus requirements available under Part 5A.2 of National Instrument 45-106, Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935, Exemptions from Certain Conditions of the Listed Issuer Financing Exemption.

About Optimi Health Corp.

Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade (good manufacturing practice) psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.

Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's authorized prescriber scheme and accessible in Canada through the special access program.

We seek Safe Harbor.